Forte Biosciences (FBRX)

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	93.41 mm	93.41 mm	93.41 mm	93.41 mm	93.41 mm	93.41 mm
Cash burn (monthly)	4.24 mm	(no burn)	6.13 mm	4.45 mm	4.67 mm	3.70 mm
Cash used (since last report)	10.27 mm	n/a	14.83 mm	10.78 mm	11.30 mm	8.96 mm
Cash remaining	83.14 mm	n/a	78.58 mm	82.64 mm	82.12 mm	84.45 mm
Runway (months of cash)	19.6	n/a	12.8	18.6	17.6	22.8

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2024

FBRX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	32	42	-23.8%
Opened positions	3	4	-25.0%
Closed positions	13	3	+333.3%
Increased positions	0	6	EXIT
Reduced positions	21	7	+200.0%

13F shares	Current	Prev Q	Change
Total value	4.13 bn	10.29 bn	-59.8%
Total shares	16.26 mm	36.35 mm	-55.3%
Total puts	0.00	0.00
Total calls	0.00	3.10 k	EXIT
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Farallon Capital Partners	3.49 mm	$0.00	0.0%
Biotechnology Value Fund L P	2.98 mm	$3.01 mm	0.0%
Funicular Funds	2.03 mm	$0.00	0.0%
BML Investment Partners	1.76 mm	$1.41 mm	0.0%
Camac Fund	1.46 mm	$819.00 k	0.0%
ATG Fund II	1.46 mm	$1.81 mm	0.0%
JEC II Associates	1.14 mm	$1.16 mm	0.0%
Funicular Fund	1.11 mm	$1.45 mm	0.0%
Tybourne Capital Management	144.98 k	$810.44 mm	-96.0%
BVF	119.28 k	$667.98 mm	-96.0%

Largest transactions	Shares	Bought/sold	Change
Tybourne Capital Management	144.98 k	-3.48 mm	-96.0%
Perceptive Advisors	95.74 k	-3.17 mm	-97.1%
BVF	119.28 k	-2.86 mm	-96.0%
Cable Car Capital	81.28 k	-1.95 mm	-96.0%
Fred Alger Management	82.70 k	-1.76 mm	-95.5%
Alger Associates	82.70 k	-1.76 mm	-95.5%
Farallon Capital Management	72.41 k	-1.74 mm	-96.0%
BML Capital Management	70.47 k	-1.69 mm	-96.0%
Vanguard	26.39 k	-638.84 k	-96.0%
Geode Capital Management	14.27 k	-332.02 k	-95.9%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

FBRX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
1 Oct 25	Wagner Paul A.	Common Stock	Payment of exercise	Dispose F	No	No	14.52	98	1.42 k	82,092
1 Oct 25	Wagner Paul A.	Common Stock	Option exercise	Acquire M	No	No	0	1,250	0.00	82,190
1 Oct 25	Wagner Paul A.	RSU Common Stock	Option exercise	Dispose M	No	No	0	1,250	0.00	6,250
1 Oct 25	Riley Antony A	Common Stock	Payment of exercise	Dispose F	No	No	14.52	134	1.95 k	31,840
1 Oct 25	Riley Antony A	Common Stock	Option exercise	Acquire M	No	No	0	375	0.00	31,974
1 Oct 25	Riley Antony A	RSU Common Stock	Option exercise	Dispose M	No	No	0	375	0.00	1,875
1 Jul 25	Wagner Paul A.	Common Stock	Payment of exercise	Dispose F	No	No	12.44	98	1.22 k	80,940
1 Jul 25	Wagner Paul A.	Common Stock	Option exercise	Acquire M	No	No	0	1,250	0.00	81,038
1 Jul 25	Wagner Paul A.	RSU Common Stock	Option exercise	Dispose M	No	No	0	1,250	0.00	7,500
1 Jul 25	Riley Antony A	Common Stock	Payment of exercise	Dispose F	No	No	12.44	134	1.67 k	31,599

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

Evercore ISI Group Initiates Coverage On Forte Biosciences with Outperform Rating, Announces Price Target of $65

25 Nov 25

Evercore ISI Group analyst Gavin Clark-Gartner initiates coverage on Forte Biosciences (NASDAQ:FBRX) with a Outperform rating and announces Price Target of $65.

Chardan Capital Maintains Buy on Forte Biosciences, Maintains $61 Price Target

17 Nov 25

Chardan Capital analyst Daniil Gataulin maintains Forte Biosciences (NASDAQ:FBRX) with a Buy and maintains $61 price target.

Forte Biosciences Q3 EPS $(0.99) Beats $(1.06) Estimate

14 Nov 25

Forte Biosciences (NASDAQ:FBRX) reported quarterly losses of $(0.99) per share which beat the analyst consensus estimate of $(1.06) by 6.43 percent. This is a 78.19 percent increase over losses of $(4.54) per share from

Forte Biosciences Highlights FB102's Efficacy in Celiac Disease at Tampere Symposium, Underscoring Histological Protection and Symptom Relief in Phase 1b Study

15 Sep 25

Press releases

From Benzinga Pro

Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules

3 Oct 25

Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as